Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.

Molecular cancer therapeutics - 1 Jan 2010

Jin Yanli, Lu Zhongzheng, Cao Kaiyuan, Zhu Yunhui, Chen Qi, Zhu Feng, Qian Chenchen, Pan Jingxuan

Abstract excerpt

Gain-of-function mutations of the receptor tyrosine kinase KIT play a critical role in the pathogenesis of systemic mastocytosis (SM) and gastrointestinal stromal tumors. The various juxtamembrane type of KIT mutations, including V560G, are found in 60% to 70% of patients with gastrointestinal st...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle
Share to Drug Screening Assays, Antitumor
Share to Gene Silencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mast Cells

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Proto-Oncogene Proteins c-bcl-2

Share to Proto-Oncogene Proteins c-kit

Share to Survival Analysis

Source

Identifiers

PMID: 20053766
DOI: 10.1158/1535-7163.MCT-09-0468

Genes

KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20053766-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.PMID 20053766Read ↗

Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.Semantic proximity Read ↗

Activity of triptolide against human mast cells harboring the kinase domain mutant KIT.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Semantic proximity Read ↗

Targeting the translational machinery in gastrointestinal stromal tumors (GIST) – a new therapeutic vulnerabilitySemantic proximity Read ↗

Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.Semantic proximity Read ↗

KIT mutations in mastocytosis and their potential as therapeutic targets.Semantic proximity Read ↗

New Insights into the Pathogenesis of Systemic Mastocytosis.Semantic proximity Read ↗

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.Semantic proximity Read ↗

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.Semantic proximity Read ↗

Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.Semantic proximity Read ↗

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.Semantic proximity Read ↗

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.